Wedbush analyst Laura Chico lowered the firm's price target on Denali Therapeutics to $23 from $25 and keeps an Outperform rating on the shares. The firm notes the Avlayah launch is now underway with initial patients receiving treatment. There is no change to Wedbush's below consensus revenue estimates as the initial quarters lay the groundwork.
